ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 325,80
0,07%
DAX
19 848,77
-0,34%
Brent Oil
72,89
-0,54%
Bitcoin
95 705,76
-3,62%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Eloxx Pharmaceuticals Inc (ELOX)

  7. Eloxx Pharmaceuticals Inc (ELOX) Actualités

ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ELOX
DateHeureSourceTitreSymboleSociété
21/08/202402h13Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ELOXEloxx Pharmaceuticals Inc
11/07/202417h46GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Pipeline and Financing UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
16/04/202413h30GlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/04/202422h02Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
29/03/202421h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/03/202419h20Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
13/03/202416h42GlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
26/01/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
25/01/202403h44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
24/01/202423h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
13/11/202322h15GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/10/202314h00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
20/09/202319h26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
19/09/202314h00GlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
18/09/202313h00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
07/09/202315h00GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
14/08/202314h30GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/08/202314h00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
11/08/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
03/08/202315h26GlobeNewswire Inc.Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementNASDAQ:ELOXEloxx Pharmaceuticals Inc
10/07/202315h00GlobeNewswire Inc.Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitNASDAQ:ELOXEloxx Pharmaceuticals Inc
28/06/202315h00GlobeNewswire Inc.Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02NASDAQ:ELOXEloxx Pharmaceuticals Inc
23/06/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELOXEloxx Pharmaceuticals Inc
21/06/202319h30GlobeNewswire Inc.Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/06/202315h00GlobeNewswire Inc.Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA CongressNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/06/202322h53GlobeNewswire Inc.Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) PatientsNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/06/202315h10GlobeNewswire Inc.Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerNASDAQ:ELOXEloxx Pharmaceuticals Inc
24/05/202314h41Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ELOXEloxx Pharmaceuticals Inc
24/05/202314h00GlobeNewswire Inc.Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 StudyNASDAQ:ELOXEloxx Pharmaceuticals Inc
15/05/202322h30GlobeNewswire Inc.Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELOX

Dernières Valeurs Consultées

COIN
FLRUSD
Flare Network
BIT
S32545
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés